進階搜尋


  查詢北醫館藏
系統識別號 U0007-3001201017520100
論文名稱(中文) 回復尋常飲食比低劑量銀杏葉萃取物對大白鼠非酒精性脂肪肝炎的進展更具有抑制效果
論文名稱(英文) Return to ordinary diet has a better inhibition than low dose of Ginkgo biloba extract on the progression ofnon-alcoholic steatohepatitis in rat
校院名稱 臺北醫學大學
系所名稱(中) 臨床醫學研究所
系所名稱(英) Graduate Institute of Clinical Medicine
學年度 98
學期 1
出版年 99
研究生(中文) 陳 永 發
研究生(英文) Yung-Fa Chen
學號 M102095032
學位類別 碩士
語文別 中文
口試日期 2009-12-26
論文頁數 91頁
口試委員 指導教授-陳盛煊
委員-楊賢馨
委員-陳俊榮
中文關鍵字 非酒精性脂肪肝炎  銀杏葉萃取物  氧化壓力  動物模式 
英文關鍵字 non-alcoholic steatohepatitis  Ginkgo biloba extract  oxidative stress  animal model 
學科別分類
中文摘要 非酒精性脂肪肝病(non-alcoholic fatty liver disease, NAFLD)在西方國家盛行率大約10 ~24%,其中約2~3%是以慢性肝炎為表現,文獻指出在5~13年的追蹤中,約三分之一的病患,其肝臟纖維化程度會加劇,最終可能會演變成肝硬化或產生肝癌,目前對於非酒精性脂肪肝炎(non-alcoholic steatohepatitis, NASH)的治療,除減重、運動來減少胰島素抗性外,並無特定療效的藥物。銀杏葉萃取物是保健的中草藥,在以往使用上並無明顯或重大的副作用,近年來發現它具有很強的清除自由基能力及抗氧化能力,所以本研究目的在於觀察銀杏葉萃取物是否對大白鼠非酒精性脂肪肝炎的進展具有預防效果。在餵食雄性Wistar大白鼠十六週液態高油脂飲食,經病理切片證實誘發NASH後,隨機分為三組:繼續液態高油飲食組(H組)、繼續液態高油飲食加銀杏葉萃取物組(HG組)及恢復尋常固型飼料組(N組),再飼養六週後犧牲,銀杏葉萃取物是採腹腔內注射,劑量為每天每公斤體重25毫克。結果發現在生化檢驗方面,HG組與H組相比只有血清三酸甘油酯及血糖為有意義的下降(P<0.05),其餘如肝功能指數、總膽固醇和血清胰島素均無差別。在肝臟生化檢驗方面,除了游離脂肪酸(free fatty acid, FFA)為有意義的下降外(P<0.01),glutathione reductase、 glutathione peroxidase(GPx)、 superoxide dismutase(SOD)、 lipid peroxidation、myeloperoxidase及tumor necrosis factor-α (TNF-α)也均無差別。另外血清TNF-α、hyaluronic acid及FFA雖有下降的趨勢,但其差別無達到統計上的意義。最後病理組織結果顯示所有HG組其NAS ( NAFLD activity score )都大於或等於五分,持續NASH的病理診斷。相反的,所有N組其NAS都小於五分,病理組織顯示脂肪堆積(P<0.01)及小葉發炎(P<0.05)與H組相比具有統計意義的下降,其次血糖、血清胰島素、肝臟FFA及血清TNF-α的下降和肝臟GPx、SOD的上昇與H組相比,亦具有統計上的差別(P<0.05)。由研究結果顯示補充六週低劑量的銀杏葉萃取物,無法明顯地減少大白鼠的氧化壓力,連帶著也無法防止大白鼠NASH的持續進展,不過經由減少飲食內脂肪的比例,來達到總熱量攝取的減少,是可以逆轉大白鼠NASH的進展。所以是否改變藥物的投予方式(例如改為口服)或延長給藥期間來增加總劑量,而達到實驗成功,是值得我們再去探討的一個議題,另外經由這實驗也證實了飲食、熱量的控制是改善NASH的首要且有效的措施。
英文摘要 The prevalence of non-alcoholic fatty liver disease (NAFLD) is about 10~24% in the West. Approximately 2~3% of the presentations about this disease were chronic hepatitis and eventually liver cirrhosis or hepatocellular carcinoma may develop. Because lack of specific efficacy of drugs except weight loss, exercise and improvement of insulin resistance, non-alcoholic steatohepatitis (NASH) will surely become an important issue in the future. Strong free radical scavenging ability and antioxidant capacity of Ginkgo biloba extract(EGb 761)has been found in recent years, so the purpose of this study is to observe whether the EGb 761 has the preventive effect on the progression of NASH. NASH confirmed by liver pathology after liquid high-fat diet feeding 16 weeks, these male Wistar rats were randomly divided and fed as following 3 groups for more 6 weeks : liquid high-fat diet group (H group), liquid high-fat diet plus EGb 761 group ( HG group) and ordinary solid diet group (N group). EGb761 was delivered by intra-peritoneal injection with the daily dose of 25 mg/ kg of body weight. Only serum triglyceride and glucose significantly decreased in HG group compared with H group in blood biochemistry(P<0.05). Others, including liver function test, total cholesterol and serum insulin had no difference between these 2 groups. Except for a significant decline of hepatic free fatty acid concentration in HG group(P<0.01), the glutathione reductase, glutathione peroxidase, superoxide dismutase, lipid peroxidation, myeloperoxidase and tumor necrosis factor-α had no difference in the liver biochemistry. Although there was a downward trend about the serum concentration of tumor necrosis factor-α, hyaluronic acid and free fatty acid in HG group compared with H group, they still can not reach significant differences. The liver pathologic results showed that the NAS (NAFLD activity score) was more than or equal to five points in all HG group. On the contrary, the NAS of rats in N group were all less than 5 points. The final results showed that the six-week supplement of low dose of EGb 761 can not significantly reduced oxidative stress and prevent the progression of NASH in rats. But it can be achieved by decreasing total calories intake with less fat content in diet. So it is worthy to investigate how to increase the total dose of EGb 761 by changing the route of delivery or extending the duration of experiment. Meanwhile this study proved that restriction of calories intake should be the first task and the most effective in management of NSAH.
論文目次 中文摘要 ……………………………………………… i
英文摘要 ……………………………………………… iii
誌謝 …………………………………………………… iv
目錄 ……………………………………………………… v
圖目錄 …………………………………………………… Vii
表目錄 …………………………………………………… Viii
第一章 緒論
第一節 前言………………………………………… 1
第二節 研究動機與目的 …………………………… 4
第二章 文獻回顧
第一節 非酒精性脂肪肝炎
一、 流行病學上的觀察 ……………………… 6
二、 致病機轉 ………………………………… 8
三、 抗氧化劑的應用 …………………………… 12
第二節 銀杏葉萃取物
一、 生理功能 ………………………………… 16
二、 臨床應用 ………………………………… 18
三、 動物實驗成果 ……………………………… 20
第三章 材料及方法
第一節 實驗動物及特殊材料 ………………………… 27
第二節 實驗設計 ……………………………………… 29
第三節 樣品收集 ……………………………………… 31
第四節 分析項目 ……………………………………… 34
第五節 統計方法 ……………………………………… 47
第四章 結果
第一節 非酒精性脂肪肝炎動物模型誘發實驗
一、 肝臟切片 ……………………………………… 48
二、 體重、肝臟重及肝臟/體重比………………… 48
三、 血液生化值 …………………………………… 49
四、 肝臟生化值 …………………………………… 49
五、 血液細胞激素及游離脂肪酸值 ……………… 50
第二節 銀杏葉萃取物及回復尋常飼料介入實驗
一、 體重、肝臟重及肝臟/體重比 ……………… 57
二、 肝臟切片 ……………………………………… 59
三、 血液生化值 …………………………………… 61
四、 肝臟生化值 …………………………………… 64
五、 血液細胞激素及游離脂肪酸值……………… 67
第五章 討論 ……………………………………………… 69
第六章 結論 ……………………………………………… 81
參考文獻 …………………………………………………… 82
參考文獻 Adachi Y, Moore LE, Bradford BU, Gao W and Thurman RG.(1995)Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 108: 218-224

Adams LA, Zein CO, Angulo P and Lindor KD (2004) A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 99:2365–2368.

Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD and Day CP (2005) Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut.54: 987-993.

Andersen T and Gluud C (1984) Liver morphology in morbid obesity: a literature study. Int J Obes.8:97-106.

Angulo P (2007) GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 25 : 883–889

Angulo P and Lindor KD (2002) Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 17 Suppl:S186-190

Anstee QM and Goldin RD (2006) Mouse models in non-alcoholic fatty liver disease
and steatohepatitis research. Int J Exp Pathol. 87:1-16.

Batman PA and Scheuer PJ (1985) Diabetic hepatitis preceding the onset of glucose intolerance. Histopathology 9:237-243

Bertram SR, Venter I and Stewart RI(1990) Weight loss in obese women—exercise
v. dietary education. S Afr Med J 78:15-18.

Bradford MM ( 1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72: 248-254

Brevoort P (1998) The booming US botanical market-a new overview. Herbalgram 44: 33-46

Brunt EM, Janney CJ, Di Bisceglie AM, Neuschwander-Tetri BA and Bacon BR (1999)
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging the Histological Lesions. Am J Gastroenterol. 94:2467-2474

Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J and Shoelson SE (2005)
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med 11:183-190

Chao CJ, Hung HC, Chen SH and Fang CL (2004) Effects of Ginkgo biloba extract on cytoprotective factors in rats with duodenal ulcer. World J Gastroenterol 10:560-566

Chen SH, Liang YC, Chao JC, Tsai LH, Chang CC, Wang CC amd Pan S (2005) Protective effects of Ginkgo biloba extract on the ethanol-induced gastric ulcer in rats. World J Gastroenterol 11:3746-3750

Cheung F, Siow YL, Chen WZ and Karmin O(1999 ) Inhibitory effect of Ginkgo biloba extract on the expression of inducible nitric oxide synthase in endothelial cells. Biochem. Pharmacol. 58:1665–1673

Crespo J, Cayón A, Fernández-Gil P, Hernández-Guerra M, Mayorga M, Domínguez- Díez A, Fernández-Escalante JC and Pons-Romero F (2001) Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology.34:1158-1163.

Curtis-prior P, Vere D and Fray P (1999) Therapeutic value of Ginkgo biloba in reducing symptoms of decline in mental function. J Pharm Pharmacol 51:535-541

Daniel S, Ben-Menachem T, Vasudevan G, Ma CK and Blumenkehl M (1999) Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol. 94:3010-3014.

Das S, Santra A, Lahiri S, Guha Mazumder DN (2005) Implications of oxidative stress and hepatic cytokine (TNF-α and IL-6) response in the pathogenesis of hepatic collagenesis in chronic arsenic toxicity. Toxicol Appl Pharmacol 204:18-26

Day CP and James OF (1998) Steatohepatitis: a tale of two "hits" ? Gastroenterology 114:842-845

Deby C, Deby-Dupont G, Dister M and Pincemail J (1993) Efficiency of Ginkgo biloba Extract(EGb761) in neutralizing ferryl ion-induced peroxidations : therapeutic implication. In: Advances in Ginkgo biloba Extract Research:Ginkgo biloba Extrxt(EGb761) as a Free-Radical Scanvenger (Ferradini C et al., ed.),Vol.2, PP.13-26. Elsevier, Paris

DeFeudis FV (1991) Ginkgo biloba extract ( Egb 761 ) Pharmacological activity and clinical applications. Paris: Editions Scientifique, Elsevier: 1-187

DeFeudis FV (1998) Ginkgo biloba extract ( Egb 761 ):from chemistry to clinic. Publr Ullestein Med and Weisbaden, Germany

Ding WX and Yin XM (2004) Dissection of the multiple mechanisms of TNF–alpha -induced apoptosis in liver injury. J Cell Mol Med. 8:445-454

Dolly M, Droy-Lefaix MT and Braquet P (1993) Retinal electrophysiology and retinotoxicity. In: Advances in Ginkgo biloba Extract Research:Ginkgo biloba Extrxt(EGb761) as a Free-Radical Scanvenger (Ferradini C et al., ed.),Vol.2, PP.66-71. Elsevier, Paris

Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD and Parks EJ (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 115: 1343–1351

Dugas AJ Jr, Castan˜ eda-Acosta J, Bonin GC, Price KL, Fischer NH and Winston GW (2000) Evaluation of the Total Peroxyl Radical-Scavenging Capacity of Flavonoids:
Structure-Activity Relationships. J Nat Prod. 63: 327-331

Duvnjak M, Lerotić I, Barsić N, Tomasić V, Virović Jukić L and Velagić V (2007). Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol.13:4539-4550.
Fan JG, Xu ZJ and Wang GL (2005) Effect of lactulose on establishment of a rat non-alcoholic steatohepatitis model. World J Gastroenterol 11:5053-5056

Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD and Gores GJ (2003) Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125:437-443

Folch J, Lees M and Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissue. J Biol Chem 226:497-509

García-Monzón C, Martín-Pérez E, Iacono OL, Fernández-Bermejo M, Majano PL, Apolinario A, Larrañaga E and Moreno-Otero R (2000) Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol.33:716-724.

Gardes-Albert M, Ferradini C, Sekaki A and Droy-Lefaix MT(1993) Oxygen-centered free radicals and their interactions with EGb 761 or CP 202.In: Advances in Ginkgo biloba Extract Research:Ginkgo biloba Extrxt(EGb761) as a Free-Radical Scanvenger (Ferradini C et al., ed.),Vol.2, PP.1-11. Elsevier, Paris

G´omez-Lech´on MJ, Donato MT, Mart´ınez-Romero A, Jim´enez N, Castell JV and O’Connor JE (2007) A human hepatocellular in vitro model to investigate steatosis. Chem Biol interact 165:106-116

Harputluoglu MM, Demirel U, Ciralik H, Temel I, Firat S, Ara C, Aladag M, Karincaoglu M and Hilmioglu F (2006) Protective effects of Gingko biloba on
thioacetamide-induced fulminant hepatic failure in rats. Hum Exp Toxicol 25 : 705-713

Harrison SA, Torgerson S, Hayashi P, Ward J and Schenker S (2003) Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98:2485–2490

Hasegawa T, Yoneda M, Nakamura K, Makino I and Terano A(2001) Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15: 1667-1672.

Hashizume H, Sato K, Takagi H, Hirokawa T, Kojima A, Sohara N, Kakizaki S, Mochida Y, Shimura T, Sunose Y, Ohwada S and Mori M (2007) Primary liver cancers with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 19:827-834.

He SX, Luo JY, Wang YP, Wang YL, Fu H, Xu JL, Zhao G and Liu EQ (2006) Effects of extract from Ginkgo biloba on carbon tetrachloride-induced liver injury in rats. World J Gastroenterol 12: 3924-3928

Huh H and Staba EJ (1992) The botany and chemistry of Ginkgo biloba. J Herbs, Spices Med Plants 1: 91-124

Jacobs BP and Browner WS (2000) Ginkgo biloba: a living fossil. Am J Med 108: 341-342

Jung HW, Chang SO, Kim CS, Rhee CS and Lim DH (1998) Effects of Ginkgo biloba extract on the cochlear damage induced by local gentamicin installation in guinea pigs. J Korean Med Sci 13:525-528

Kao JH and Chen DS (2002) Global control of hepatitis B virus infection. Lancet Infect Dis. 2:395-403

Kirsch R, Clarkson V, Verdonk RC, Marais AD, Shephard EG, Ryffel B and de la M Hall P (2006) Rodent nutritional model of steatohepatitis: Effects of endotoxin
(lipopolysaccharide) and tumor necrosis factor alpha deficiency. Journal of Gastroenterology and Hepatology 21: 174–182

Kleijnen J and Knipschild P (1992) Ginkgo biloba. Lancet 340:1136-1139

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ and Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network(2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321.

Kudo H, Takahara T , Yata Y, KawaiK , Zhang W and Sugiyama T (2009) Lipopolysaccharide triggered TNF-a-induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model. Journal of Hepatology 51 : 168–175

Kudolo GB (2001) The effect of 3-month ingestion of Ginkgo bioloba extract (Egb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus. Journal of Clinical Pharmacology 41: 600–611.

Lai MY (2006) Combined Interferon and RibavirinTherapy for Chronic Hepatitis C in Taiwan. Intervirology 49:91–95

Lai SW, Tan CK and Ng KC (2002) Epidemiology of fatty liver in a hospital-based study in Taiwan. South Med J 95:1288-1292

Le Bars PL and Kastelan J (2000) Efficacy and safety of a Ginkgo biloba extract. Pub Health Nutr 3: 495-499.

Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM and Schatzberg AF(1997) A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 278: 1327-1332.

Liaw YF and Chu CM (2009) Hepatitis B virus infection. Lancet. 373:582-592

Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A and Decarli LM (2004) Model of Nonalcoholic steatohepatitis. Am J Clin Nutr 79:350-351.

Lien EJ, Ren S, Bui HH and Wang R (1999) Quantitative structure-activity relationship analysis of phenolic antioxidants. Free Radic Biol Med 26:285-294

Liu SQ, YuJP, Chen HL, Luo HS, Chen SM and Yu HG (2006) Therapeutic Effects and Molecular Mechanisms of Ginkgo Biloba Extract on Liver Fibrosis in Rats. Am J Chin Med. 34 : 99-114

Logani S, Chen MC, Tran T, Le T and Raffa RB(2000). Actions of Ginkgo biloba related to potential utility for the treatment of conditions involving cerebral hypoxia. Life Sciences 67:1389-1396

Ludwig J, Viggiano TR, McGill DB and Oh BJ (1980) Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434-38

Luo YJ, Yu JP, Shi ZH and Wang L(2004) Ginkgo biloba extract reverses Cl4 –induced liver fibrosis in rats. World J Gastroenterol 10:1037-1042

Mahady GB (2001) Ginkgo biloba: a review of quality, safety, and efficacy. Nutr Clin Care 4: 140-147.

Malhi H, Bronk SF, Werneburg NW and Gores GJ (2006) Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 281:12093-12101

Marchesini G, Brizi M, Marsell-Labate AM, Bianchi G, Buqianesi E, Mccullough AJ, Forlani C and Melchionda N (1999) Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107:450-455

Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascian`a R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, and Grieco1 A (2009) Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology, 49: 1877-1887

Nagai H, Matsumaru K, Feng G and Kaplowitz N (2002) Reduced glutathione depletion causes necrosis and sensitization to tumor necrosis factor-alpha-induced apoptosis in cultured mouse hepatocytes. Hepatology. 36:55-64.

Naik SR and Panda VS (2007) Antioxidant and hepatoprotective effects of Ginkgo biloba phytosomes in carbon tetrachloride-induced liver injury in rodents. Liver Int. 27 : 393-399

Neuner P, Klosner G, Schauer E, Pourmojib M, Macheiner W, Grünwald C, Knobler R, Schwarz A, Luger TA and Schwarzet T (1994). Pentoxifylline in vivo down- regulates the release of IL-1 beta, IL-6, IL-8, and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 83:262–267.

Oh MK, Winn J and Poordad F (2008) Review article: diagnosis and treatment of non- alcoholic fatty liver disease. Aliment Pharmacol Ther 28: 503–522

Oken BS, Storzbach DM and Kaye JA(1998) The efficacy of Ginkgo biloba extract on cognitive function in Alzheimer disease. Arch Neurol 55: 1409-1415.

Pener G, Kabasakal L, Yüksel M, Gedik N and Alican Y (2005) Hepatic fibrosis in biliary-obstructed rats is prevented by Ginkgo biloba treatment. World J Gastroenterol 11:5444-5449

Pessayre D, Fromenty B and Mansouri A (2004) Mitochondrial injury in steatohepatitis
Eur J Gastroenterol Hepatol 16:1095-1105

Pittler MH and Ernst E (2000) Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med 108: 276-281.

Rapin JR, Yoa RG, Bouvier C and Drieu K(1997) Effects of repeated treatments with an extract of Ginkgo biloba (EGb 761) and bilobalide on liver and muscle glycogen contents in the non-insulin-depedent diabetic rat. Drug Development Research 40: 68–74.

Ribeiro PS, Cortez-Pinto H, Solá S, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME and Rodrigues CM (2004) Hepatocyte Apoptosis, Expression of Death Receptors, and Activation of NF-κB in the Liver of Nonalcoholic and Alcoholic Steatohepatitis Patients. Am J Gastroenterol 99: 1708–1717

Samuel VT, Liu ZX,Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, and Shulman GI (2004) Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease. J. Biol. Chem. 279: 32345-32353

Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML and Clore JN (2001) Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120:1183-1192

Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC and Sarm SK (2004). Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 99:1946–1952.

Satapathy SK, Sakhuja P, Malhotra V, Sharma BC and Sarm SK (2007) Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis, and necroinflammation in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 22:634–638.

Schaffner F and Thaler H (1986) Nonalcoholic fatty liver disease. Prog Liver Dis 8:283-298

Sener G, Omurtag GZ, Sehirli O¨, Tozan A, Y¨uksel M, Ercan F and Gedik N (2006) Protective effects of Ginkgo biloba against acetaminophen-induced toxicity in mice. Molecular and Cellular Biochemistry 283: 39–45

Shen J, Wang J, Zhao B, Hou J, Gao T and Xin W(1998) Effects of EGB 761 on nitric oxide and oxygen free radicals, myocardial damage and arrhythmia in ischemia– reperfusion injury in vivo. Biochem Biophys. Acta 28: 228–236, 1998

Smith JY and Luo Y(2004) Studies on molecular mechanisms of Ginkgo biloba extract. Applied Microbiology and Biotechnology 64, 465–472.

Szabo ME, Droy-Lefaix MT and Doly M(1993) Reduction of reperfusion-induced ionic
imbalance by the superoxide dismutase, vitamin E and Ginkgo biloba Extract 761 in spontaneously hypertensive rat retina. In: Advances in Ginkgo biloba Extract Research:Ginkgo biloba Extrxt(EGb761) as a Free-Radical Scanvenger (Ferradini C et al., ed.),Vol.2, PP.93-106. Elsevier, Paris

Tanaka S, Han LK, Zheng YN and Okuda H( 2004) Effects of the flavonoid fraction from Ginkgo biloba extract on the postprandial blood glucose elevation in rats. Yakugaku Zasshi 124: 605–611.

Thurman RG, Bradford BU, Iimuro Y, Knecht KT, Arteel GE, Yin M, Connor HD, Wall C, Raleigh JA, Frankenberg MV, Adachi Y, Forman DT, Brenner D, Kadiiska M and Mason RP.(1998)The role of gut-derived bacterial toxins and free radicals in alcohol-induced liver injury. J Gastroenterol Hepatol 13 (Suppl): S39-50

Varga, E, Bodi A, Ferdinandy P, Droy-Lefailax MT, Blasig LE and Tosaki A(1999) The protective effect of EGB 761 in isolated ischemic/reperfused rat hearts: a link between cardiac function and nitric oxide production. J. Cardiovasc. Pharmacol. 34: 711–717

Watanabe S, Yaginuma R, Ikejima K and Miyazaki A (2008) Liver diseases and metabolic syndrome. J Gastroenterol 43:509-518

West D.B, Boozer C.N, Moody D.L and Atkinson R.L. (1992) Dietary obesity in nine inbred mouse strains. Am. J. Physiol. 262: R1025–R1032.

Yakaryilmaz F, Guliter S, Ozenirler S, Erdem O and Akyol G (2004) Vitamin E treatment in patients with nonalcoholic steatohepatitis: A six-month, open-label study of sixteen patients. Curr Ther Res Clin Exp 65: 266–277
Yakaryilmaz F, Guliter S, Savas B, Erdem O, Ersoy R, Erden E, Akyol G, Bozkaya H and Ozenirler S (2007) Effects of vitamin E treatment on peroxisome proliferator -activated receptor-α expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern Med J 37:229-235

Yao P, Li K, Song F, Zhou S, Sun X , Zhang X, Nussler AK and Liu L (2007) Heme oxygenase-1 upregulated by Ginkgo biloba extract: Potential protection against ethanol-induced oxidative liver damage. Food Chem Toxicol 45 : 1333-1342

Younossi ZM, Gramlich T, Matteoni CA, Boparai N and McCullough AJ (2004)
Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2:262-265

Yuan G, Gong Z, Li J and Li X (2006) Ginkgo biloba Extract Protects against Alcohol- induced Liver Injury in Rats. Phytother. Res. 21, 234–238

Zamara E, Novo E, Marra F, Gentilini A, Romanelli RG, Caligiuri A, Robino G, Tamagno E, Aragno M, Danni O, Autelli R, Colombatto S, Dianzani MU, Pinzani M and Parola M (2004) 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol 40:60-80

Zhang C, Zu J, Shi H, Liu J and Qin C (2004) The effect of Ginkgo biloba extract (EGb 761) on hepatic sinusoidal endothelial cells and hepatic microcirculation in CCl4 rats. Am J Chin Med 32 : 21-31
論文全文使用權限
  • 同意授權瀏覽/列印電子全文服務,於2011-02-09起公開。


  • 若您有任何疑問,請與我們聯絡!
    臺北醫學大學 圖書館 簡莉婷
    E-mail:etds@tmu.edu.tw
    Tel:(02) 2736-1661 ext.2519
    Fax:(02) 2737-5446